Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 5, 2014
|
| In: |
The lancet. Oncology
Year: 2014, Jahrgang: 15, Heft: 4, Pages: 415-423 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(14)70063-4 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(14)70063-4
|
| Verfasserangaben: | Ian Judson, Jaap Verweij, Hans Gelderblom, Jörg T Hartmann, Patrick Schöffski, Jean-Yves Blay, J Martijn Kerst, Josef Sufl iarsky, Jeremy Whelan, Peter Hohenberger, Anders Krarup-Hansen, Thierry Alcindor, Sandrine Marreaud, Saskia Litière, Catherine Hermans, Cyril Fisher, Pancras C W Hogendoorn, A Paolo dei Tos, Winette T A van der Graaf, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1550125044 | ||
| 003 | DE-627 | ||
| 005 | 20220813092103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 161124s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(14)70063-4 |2 doi | |
| 035 | |a (DE-627)1550125044 | ||
| 035 | |a (DE-576)48012504X | ||
| 035 | |a (DE-599)BSZ48012504X | ||
| 035 | |a (OCoLC)1340944584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Judson, Ian |e VerfasserIn |0 (DE-588)1120049466 |0 (DE-627)873177428 |0 (DE-576)480124590 |4 aut | |
| 245 | 1 | 0 | |a Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma |b a randomised controlled phase 3 trial |c Ian Judson, Jaap Verweij, Hans Gelderblom, Jörg T Hartmann, Patrick Schöffski, Jean-Yves Blay, J Martijn Kerst, Josef Sufl iarsky, Jeremy Whelan, Peter Hohenberger, Anders Krarup-Hansen, Thierry Alcindor, Sandrine Marreaud, Saskia Litière, Catherine Hermans, Cyril Fisher, Pancras C W Hogendoorn, A Paolo dei Tos, Winette T A van der Graaf, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
| 264 | 1 | |c March 5, 2014 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am: 24.11.2016 | ||
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 15(2014), 4, Seite 415-423 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma a randomised controlled phase 3 trial |
| 773 | 1 | 8 | |g volume:15 |g year:2014 |g number:4 |g pages:415-423 |g extent:9 |a Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma a randomised controlled phase 3 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(14)70063-4 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(14)70063-4 |q application/pdf |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20161124 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |d 61800 |e 60000PH1025311469 |e 61800PH1025311469 |k 0/60000/ |k 1/60000/61800/ |p 10 | ||
| 999 | |a KXP-PPN1550125044 |e 2946294781 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"roleDisplay":"VerfasserIn","role":"aut","display":"Judson, Ian","given":"Ian","family":"Judson"},{"family":"Hohenberger","given":"Peter","display":"Hohenberger, Peter","roleDisplay":"VerfasserIn","role":"aut"}],"note":["Gesehen am: 24.11.2016"],"recId":"1550125044","language":["eng"],"physDesc":[{"extent":"9 S."}],"relHost":[{"id":{"zdb":["2035574-9"],"issn":["1474-5488"],"eki":["325349770"]},"origin":[{"publisher":"The Lancet Publ. Group","publisherPlace":"London","dateIssuedKey":"2000","dateIssuedDisp":"2000-"}],"part":{"issue":"4","text":"15(2014), 4, Seite 415-423","pages":"415-423","volume":"15","extent":"9","year":"2014"},"pubHistory":["0.2000 -"],"titleAlt":[{"title":"The lancet <London> / Oncology"}],"title":[{"title":"The lancet","title_sort":"lancet","partname":"Oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"325349770","language":["eng"],"note":["Gesehen am 22.09.2021"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma a randomised controlled phase 3 trialThe lancet. Oncology"}],"origin":[{"dateIssuedDisp":"March 5, 2014","dateIssuedKey":"2014"}],"id":{"eki":["1550125044"],"doi":["10.1016/S1470-2045(14)70063-4"]},"name":{"displayForm":["Ian Judson, Jaap Verweij, Hans Gelderblom, Jörg T Hartmann, Patrick Schöffski, Jean-Yves Blay, J Martijn Kerst, Josef Sufl iarsky, Jeremy Whelan, Peter Hohenberger, Anders Krarup-Hansen, Thierry Alcindor, Sandrine Marreaud, Saskia Litière, Catherine Hermans, Cyril Fisher, Pancras C W Hogendoorn, A Paolo dei Tos, Winette T A van der Graaf, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group"]},"title":[{"title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma","title_sort":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma","subtitle":"a randomised controlled phase 3 trial"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a JUDSONIANHDOXORUBICI5201 | ||